Aripiprazole 20 mg Tablets Recalled for Manufacturing Quality Deviations
Accord Healthcare is recalling 170,448 bottles of Aripiprazole 20 mg tablets distributed in the United States, Puerto Rico, and Canada due to manufacturing quality control (CGMP) deviations identified during FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for a prescription medication due to manufacturing and quality control deviations. No illnesses or injuries have been reported. Per the rubric, Class II recalls with no reported harm but representing potential risk-of-harm to patients qualify as 'High' (score 3).
Plain-English summary
Accord Healthcare, Inc. is recalling 170,448 bottles of Aripiprazole Tablets, USP 20 mg, distributed throughout the United States, including Puerto Rico and Canada. The affected product is a generic antipsychotic available in 30-count bottles (NDC 16729-282-10) and 100-count bottles (NDC 16729-282-01).
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations. CGMP deviations indicate that the manufacturing, processing, or quality control procedures did not meet federal regulatory standards.
Multiple batch codes are affected, with expiration dates ranging from January 2024 through August 2025.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Antipsychotic
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (14)
- Batches: a) P2100787
- P2100788
- Exp. Date 1/31/2024
- P2104736
- Exp. Date 6/30/2024
- P2105492
- Exp. Date 8/31/2024
- P2107172
- P2107175
- Exp. Date 10/31/2024
- P2203043
- Exp. Date 5/31/2025
- b) P2104086 Exp. Date 6/30/2024
- P2205370 Exp. 8/31/2025
UPCs (2)
- 316729282109
- 316729282017
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27